Announced details
Perioperative management for elective surgery involving pancreaticoduodenectomy or surgery for hilar cholangiocarcinoma. Patient self-management of diet, medication, rehabilitation and walking; nutritional management; rehabilitation; and surgical explanations.
Joint research between PSP株式会社 and the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. PSP株式会社 is a consolidated subsidiary of TECHMATRIX CORPORATION, which holds a 50.02% stake. The Cancer Institute Hospital of the Japanese Foundation for Cancer Research will implement the PERICAN app and evaluate perioperative management and healthcare professional workflows, while PSP株式会社 will develop the app and manage the system.
Located in Koto-ku, Tokyo, the hospital is operated by the Japanese Foundation for Cancer Research, a public interest incorporated foundation whose research institute and hospital work together on research and medical care related to the diagnosis, treatment and prevention of cancer. The hospital director is Sano Takeshi (佐野 武).
Koto-ku, Tokyo (Cancer Institute Hospital)
No impact on financial performance is stated.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | NOBORI, PERICAN app, Cancer Institute Program PERICAN |
| Counterparty | The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Cancer Institute Hospital) |
| Counterparty overview | Located in Koto-ku, Tokyo, the hospital is operated by the Japanese Foundation for Cancer Research, a public interest incorporated foundation whose research institute and hospital work together on research and medical care related to the diagnosis, treatment and prevention of cancer. The hospital director is Sano Takeshi (佐野 武). |
| Relationship with the Company | Joint research between PSP株式会社 and the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. PSP株式会社 is a consolidated subsidiary of TECHMATRIX CORPORATION, which holds a 50.02% stake. The Cancer Institute Hospital of the Japanese Foundation for Cancer Research will implement the PERICAN app and evaluate perioperative management and healthcare professional workflows, while PSP株式会社 will develop the app and manage the system. |
| Launch date | April 2026 (planned study start) |
| Applicable area | Perioperative management for elective surgery involving pancreaticoduodenectomy or surgery for hilar cholangiocarcinoma. Patient self-management of diet, medication, rehabilitation and walking; nutritional management; rehabilitation; and surgical explanations. |
| Location | Koto-ku, Tokyo (Cancer Institute Hospital) |
| Impact on Business Performance | No impact on financial performance is stated. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The paper-based ERAS process faces challenges including low patient adherence, difficulty evaluating and managing implementation, and increased workloads for healthcare professionals as the number of eligible patients grows. The app is intended to encourage behavioral change, improve postoperative outcomes and the quality of perioperative management, and reduce the burden on healthcare professionals.